Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05883462
Other study ID # RESTORE-1
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date June 7, 2023
Est. completion date December 2029

Study information

Verified date August 2023
Source Airiver Medical, Inc.
Contact Yan Li, MD
Phone 6513530685
Email liy@airiver.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It is a first in human (FIH) study to evaluate safety, and potential efficacy of Airiver Nasal DCB in the treatment of recurrent CRSwNP or CRSsNP. Participants will receive AIRIVER Nasal drug-coated balloon treatment.


Description:

Paclitaxel coated balloon is designed to offer both mechanical dilation of nasal obstruction and local drug effect for underlying inflammatory disorder and cell hyperplasia. It is hypothesized that Airiver Nasal drug-coated balloon (DCB) will improve patient outcome and as an adjunct to standard of care, will improve nasal patency than the standard of care alone. This is a prospective, single arm, first in human (FIH) study.


Recruitment information / eligibility

Status Recruiting
Enrollment 45
Est. completion date December 2029
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Up to 45 CRS subjects with recurrent symptomatic nasal obstruction eligible for Airiver Nasal DCB treatment 1. Males or females, =18 years 2. Signed written informed consent 3. Recurrent, symptomatic CRS (with or without nasal polyps, with or without prior sinus surgery), have: - Moderate or severe nasal congestion/blockage/obstruction - AND decreased or loss of smell (hyposmia or anosmia), - Or rhinorrhea (anterior/posterior) - For recurrent CRSwNP: 1. candidates for RESS or other treatment due to recurrent symptom, and endoscopically confirmed present with unilateral or bilateral polyps, and/or unilateral or bilateral mucosal disease confirmed by nasal endoscopy and/or CT 2. bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or had a medical contraindication / intolerance to SCS 3. with or without Aspirin-Exacerbated Respiratory Disease (AERD) - For recurrent CRSsNP: refractory to optimal medical treatment and/or previous surgery with positive CT scan of the sinuses mucosal thickening and obstruction or positive nasal endoscopic finding (purulence or edema) 4. Acute Exacerbation of CRS (AECRS) 5. Subjects with comorbid asthma or COPD must be stable with no exacerbations (e.g., no emergency room visits, hospitalizations) for 6 months before the screening visit Exclusion Criteria: 1. Pediatric CRS (PCRS) 2. Acute bacterial sinusitis (ABRS), acute rhinosinusitis (ARS), or mycetoma and invasive fungal sinusitis 3. Malignancy 4. Experienced a cerebrospinal fluid (CSF) leak in prior skull-based dehiscence 5. Symptomatic without positive CT findings or an asymptomatic 6. Subjects whose symptoms are too severe (eg, temperature >102.58F or extrasinus manifestations, such as orbital cellulitis; dental or facial or brain abscess; cavernous vein thrombosis; or altered mental status 7. Primary ciliary dyskinesia (PCD) 8. Unable to have nasal cavity examination due to septal deviation or spur. Participants who had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NP 9. Have evidence of significant baseline mucosal injury, ulceration, or erosion (eg, exposed cartilage, perforation) on baseline nasal examination 10. Purulent nasal infection, or upper respiratory tract infection within 2 weeks before the screening visit. Potential subjects presenting with any of these infections may be rescreened 4 weeks after symptom resolution 11. Allergy or hypersensitivity to any excipients and paclitaxel. 12. Patient has an inability to tolerate endoscopy 13. Suffering or recovering from COVID-19 (Fully recovered Covid-19 patients is not excluded) 14. Study subject has any disease or condition that interferes with safe completion of the study, such as severe COPD or severe asthma 15. Subjects with abnormal screening laboratory/imaging test results that compromise the ability to assess the benefits/risks (eg, abnormal ECG) 16. Pregnancy or planning on pregnant during the first 12 months of enrollment in the study 17. Life expectancy <1 year 18. Patient is currently enrolled in other current investigational studies. Participation in studies for products approved in the US are not considered investigational. 19. Lack of informed consent 20. Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener's granulomatosis), Young's syndrome, Kartagener's syndrome or other dyskinetic ciliary syndromes -

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Airiver Nasal Drug Coated Balloon (DCB) Catheter.
The balloon is coated with a paclitaxel drug (3.5ug/mm2).

Locations

Country Name City State
Paraguay Sanatorio Americano Hospital Asunción

Sponsors (1)

Lead Sponsor Collaborator
Airiver Medical, Inc.

Country where clinical trial is conducted

Paraguay, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary safety: Freedom from major device related adverse events (MADE) post index procedure assessed by the proportion of subjects free from the primary safety event through 30 days. Subjects failing any component of the primary safety endpoint will be considered a safety failure, and subjects who remain event free through 30 days will be considered safety successes. MADE is defined as: 1) Cerebrospinal fluid (CSF) leak, 2) Severe epistaxis (nasal bleeding) requiring intervention other than packing, 3) Eye complication requiring surgical treatment, 4) Paclitaxel related nasal mucosal disorder. 30 days
Primary Primary efficacy: Freedom from target lesion reintervention due to recurrence of CRS without nasal polyposis or CRS with nasal polyposis (retuning to baseline symptoms or worse) through 6 months. assessed by Kaplan-Meier survival analysis of the incidence of subjects free from symptom-driven TLR. 6 months
Secondary Incidence of, and time to symptom-driven reintervention assessed by Kaplan-Meier survival analysis of the incidence of subjects free from symptom-driven TLR 12 months
Secondary Change in patient reported 22-item Sino-Nasal Outcome Test (SNOT-22) from the baseline Total SNOT 22 score is between 0 to 110. Higher scores indicate worse rhinosinusitis. 12 months
Secondary Change in Lund-Kennedy Endoscopic Scores from the baseline The scores range is from 0 to 20. Higher scores indicate worse observed disease. 12 months
Secondary Change in Lund-Mackay computed tomography (LMK-CT) score from the baseline The score range is from 0 to 24. Higher scores indicate worse disease severity. 12 months.
Secondary Change of Health-related quality -of- life (HRQL) from the baseline (Euro-QOL-5D questionnaire) The EQ-5D essentially consists of 2 parts: the EQ-5D descriptive system and the EQ VAS. The EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ VAS records the respondent's self-rated health on a vertical VAS. The EQ VAS 'thermometer' has scales of 100 (Best imaginable health state) at the top and 0 (Worst imaginable health state) at the bottom. 12 months
Secondary Change in sense of smell using the University of Pennsylvania Smell Identification Test (UPSIT) from the baseline The score range is between 0-40. Higher scores indicate better smell function. 12 months
Secondary Clinical pharmacokinetics of paclitaxel in 15 subjects Blood samples will be collected at baseline and post procedure at pre-designated time points and assessed for plasma paclitaxel concentrations. 10 days
Secondary Change in Asthma Control Questionnaire-6 (ACQ-5) Scores from baseline for subjects with comorbid asthma A score of 0-6 is assigned to values for each criterion. The total ACQ score is the mean value calculated after adding the individual scores for each criterion. In general, patients with a score below 1.0 are likely to have adequately controlled asthma, above 1.0 their asthma is not likely to be well-controlled. 12 months
Secondary Nasal DCB performance evaluation in index procedures Device Performance will be assessed using a rating scale (1-5) to evaluate seven aspects of the test article. Higher scores indicate better performance. one day
See also
  Status Clinical Trial Phase
Completed NCT04131686 - NAC Inhalation in the Treatment Of Symptomatic acuTe rhinosinUSitis
Completed NCT02692794 - Large Scale Cerebral Oximetry During Sinus Endoscopy N/A
Completed NCT01988779 - Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations Phase 3
Completed NCT01254916 - The Sinonasal Outcome Test - 22, Validated for Danish Patients N/A
Completed NCT03614923 - Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Phase 2
Completed NCT03781804 - Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps Phase 3
Completed NCT01198912 - Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial Phase 2
Active, not recruiting NCT06457100 - Esmolol Versus Lidocaine on the Quality of Postoperative Recovery in Patients Undergoing Functional Endoscopic Sinus Surgery Phase 1/Phase 2
Completed NCT03280537 - A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps Phase 3
Terminated NCT02285283 - Itraconazole for Fungal Sensitive Chronic Rhinosinusitis With Nasal Polyps Phase 2/Phase 3
Completed NCT02307825 - Azithromycin for Patients With Chronic Rhinosinusitis Failing Medical and Surgical Therapy Phase 4
Completed NCT02218307 - The Use of Antibiotic Sinonasal Rinse After Sinus Surgery Phase 4
Recruiting NCT01024075 - Effect of Sinufoam-Dexamethasone Mixture on Post Endoscopic Sinus Surgery Outcomes Phase 4
Completed NCT01002313 - Effect of Prednisone onTregs and TH17 Phase 1
Completed NCT00396162 - Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis Phase 4
Completed NCT03280550 - A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps Phase 3
Recruiting NCT05935683 - Rhinosinusitis Italian Network: the Italian Registry for Severe, Uncontrolled Chronic Rhinosinusitis
Completed NCT03478930 - An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps Phase 3
Completed NCT01943370 - Early Saline Irrigation to Decrease Post-operative Endoscopic Debridement N/A
Completed NCT02154555 - A Randomized Controlled Trial Evaluating Postoperative Debridement Following Endoscopic Sinus Surgery N/A